Precision BioSciences (DTIL) News Today $7.23 +0.08 (+1.12%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.48 +0.25 (+3.44%) As of 05/22/2026 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DTIL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver ...May 22 at 1:23 AM | uk.finance.yahoo.comPrecision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026May 21 at 7:01 AM | businesswire.comPrecision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual MeetingMay 14, 2026 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Precision BioSciences (DTIL)May 12, 2026 | theglobeandmail.comPrecision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPSMay 5, 2026 | marketbeat.comPrecision BioSciences Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 5, 2026 | businesswire.comPrecision BioSciences (DTIL) Projected to Post Earnings on TuesdayMay 2, 2026 | marketbeat.comPrecision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026April 30, 2026 | businesswire.comPrecision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD StudyApril 29, 2026 | tmcnet.comPrecision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual MeetingApril 28, 2026 | businesswire.comPrecision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)April 24, 2026 | businesswire.comPrecision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference TranscriptApril 15, 2026 | seekingalpha.comPrecision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European CountriesApril 15, 2026 | businesswire.comPrecision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | businesswire.comPrecision BioSciences, Inc. (DTIL) Shareholder/Analyst Call TranscriptMarch 17, 2026 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Precision BioSciences (DTIL)March 12, 2026 | theglobeandmail.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | tmcnet.comPrecision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV ProgramMarch 11, 2026 | businesswire.comPrecision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical ...March 10, 2026 | tmcnet.comPrecision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy studyMarch 10, 2026 | msn.comPrecision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026March 10, 2026 | businesswire.comPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026March 9, 2026 | businesswire.comPrecision BioSciences shares jump after FDA grants fast track status to Duchenne therapyMarch 9, 2026 | msn.comPrecision BioSciences stock jumps on FDA Fast Track statusMarch 9, 2026 | za.investing.comPrecision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor EventMarch 9, 2026 | businesswire.comPrecision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple SclerosisMarch 2, 2026 | businesswire.comInsider Selling: Precision BioSciences (NASDAQ:DTIL) Insider Sells $18,912.00 in StockFebruary 20, 2026 | insidertrades.comPrecision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular DystrophyFebruary 11, 2026 | businesswire.comJonesTrading Keeps Their Buy Rating on Precision BioSciences (DTIL)January 24, 2026 | theglobeandmail.comJ. Jefferson Smith Sells 10,200 Shares of Precision BioSciences (NASDAQ:DTIL) StockJanuary 23, 2026 | insidertrades.comPrecision BioSciences Highlights 2026 Gene Editing PrioritiesJanuary 15, 2026 | theglobeandmail.comPrecision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for ...January 12, 2026 | finance.yahoo.comPrecision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular DystrophyJanuary 12, 2026 | businesswire.comPrecision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026December 29, 2025 | seekingalpha.comPrecision BioSciences (NASDAQ:DTIL) Director Acquires $12,690.00 in StockDecember 18, 2025 | insidertrades.comPrecision BioSciences (DTIL) Receives a Rating Update from a Top AnalystDecember 13, 2025 | theglobeandmail.comPrecision Biosciences: Still Swinging And Finally Drawing BloodDecember 4, 2025 | seekingalpha.comPrecision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025November 19, 2025 | businesswire.comPrecision BioSciences (DTIL) Price Target Decreased by 10.55% to 33.15November 18, 2025 | msn.comPrecision BioSciences Announces $70M Stock OfferingNovember 14, 2025 | theglobeandmail.comPrecision BioSciences announces presentation from PBGENE-HBV studyNovember 12, 2025 | msn.comPrecision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B TranscriptNovember 11, 2025 | seekingalpha.comPrecision BioSciences announces $75M offering of common stock, warrantsNovember 10, 2025 | msn.comPrecision BioSciences Unveils Promising ELIMINATE-B Trial ResultsNovember 10, 2025 | msn.comPrecision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and WarrantsNovember 10, 2025 | businesswire.comPrecision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three CohortsNovember 10, 2025 | businesswire.comPrecision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 3, 2025 | businesswire.comPrecision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns climbed after last week's 24% gain, institutional investors must be happyOctober 31, 2025 | finance.yahoo.comPrecision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025October 31, 2025 | businesswire.comPrecision BioSciences Advances with Promising Hepatitis B Gene-Editing StudyOctober 28, 2025 | msn.com Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DTIL Media Mentions By Week DTIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DTIL News Sentiment▼0.000.45▲Average Medical News Sentiment DTIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DTIL Articles This Week▼23▲DTIL Articles Average Week Get the Latest News and Ratings for DTIL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Precision BioSciences and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Design Therapeutics News CryoPort News CytomX Therapeutics News Aclaris Therapeutics News CorMedix News Gyre Therapeutics News Tilray Brands News Zevra Therapeutics News Solid Biosciences News EIKN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DTIL) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
